Clinical cancer genomics: how soon is now?
Germline and somatic alterations in DNA mediate the genesis and progression of human cancers. Not only do these events represent the molecular underpinnings of disease but many are of immense clinical importance as diagnostic markers and therapeutic targets. In fact, rapidly evolving sequencing technologies have empowered enormous growth in the breadth and depth of cancer genome characterization. Whether these will impact routine clinical practice and the treatment of disease is no longer debatable, but how precisely this will happen is a source of ongoing speculation and development.
Program in Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. taylorb@cbio.mskcc.org
Barry S
BS
Taylor
Marc
M
Ladanyi
D020022:Genetic Predisposition to Disease; D023281:Genomics; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy; D057285:Precision Medicine / Q000379:methods